Finance News Lindis Blood Care Announces Positive Top-Line Results from Clinical Certification Study REMOVE with CATUVAB® to Enable Autologous Blood Transfusion in Cancer Surgeries Hennigsdorf [...]
Finance News Lindis Blood Care to Present Top Line Results from Clinical Certification Study REMOVE with CATUVAB® at NATA24 Annual Symposium Hennigsdorf (Berlin), Germany: April [...]
Finance News Lindis Blood Care Announces Last Patient Out in Multicenter Clinical Certification Study REMOVE with CATUVAB® to Eliminate Tumor Cells from Surgical Blood Hennigsdorf [...]
Finance News Lindis Blood Care Announces Last Patient Out in Multicenter Clinical Certification Study REMOVE with CATUVAB® to Eliminate Tumor Cells from Surgical Blood Hennigsdorf (Berlin), [...]
Finance News Lindis Blood Care successfully closes follow-on financing round Hennigsdorf, Germany – 9th February, 2022. Funding round supported by High-Tech Gründerfonds (HTGF), Brandenburg Kapital [...]
Finance News Lindis Blood Care Announces Publication of Clinical Pilot Study Results Successfully Highlighting the Potential of CATUVAB® in the Removal of Tumor Cells from [...]
Finance News Tumorzellfreies Eigenblut bei Krebsoperationen Hennigsdorf (Berlin), Germany: September 3, 2021. Aus dem brandenburgischen Hennigsdorf kommt eine Innovation, die als neuer „Goldstandard“ die Eigenbluttransfusion [...]
Finance News Lindis’ Catuvab is designed to remove tumor cells from surgical blood Hennigsdorf, Berlin, Germany - April 2, 2021. Lindis Blood Care GmbH launched [...]
Finance News Lindis Blood Care Initiates Multicenter Clinical EU Certification Study REMOVE with CATUVAB® to Eliminate Tumor Cells from Surgical Blood Hennigsdorf, Berlin, Germany - [...]
Finance News Over 5 million euros for Lindis Blood Care: development of a new product for the removal of tumor cells from surgical blood Hennigsdorf [...]
